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do the cell-wall of pretreated Lactococcus lactis, designated as Gram-positive enhancer matrix (GEM), by means of a peptidoglycan binding
omain. The influence of the GEM particles on the antigen-specific serum antibody response was studied. Following nasal immunization with
he GEM-based vaccines, antibody responses were induced at systemic and local levels. Furthermore, different GEM-based vaccines could
e used consecutively in the same mice without adverse effects or loss of activity. Taken together, the results evidence the adjuvant properties
f the GEM particles and indicate that GEM-based vaccines can be used repeatedly and are particularly suitable for nasal immunization
urposes.
2006 Elsevier Ltd. All rights reserved.
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. Introduction
In the past years considerable effort has been undertaken
o develop mucosal vaccines and to understand mechanisms
nderlying mucosal immunity (for recent reviews see [1,2]).
he nasal and oral routes are very attractive considering the
ase of administration and the local immune response at the
ontact surface between the body and the outside world. In the
uture, mucosal vaccines may partly replace injectable vac-
ines provided that potent and relevant responses are elicited.
lthough encouraging results have been reported, improve-
ents are still required, both in terms of efficiency and safety.
Most adjuvants with potency for mucosal immunization
re derived from bacteria. They include the well-known
holera toxin and Escherichia coli heat-labile toxin as well as
∗ Corresponding author. Tel.: +31 50 3638146; fax: +31 50 3634429.
E-mail address: leenhouts@biomade.nl (K.J. Leenhouts).
their non-toxic variants, muramyl di-peptide [3], outer mem-
brane proteins [4,5] and outer membrane vesicles [6] of e.g.
Neisseria meningitidis. Whole cell Bordetella pertussis and
N. meningitidis also provided nice results in animal models
[7,8]. However, the use of pathogen-based vaccines/adjuvants
is associated with safety concerns and the current research
aims at finding alternatives. In this context, the lactic acid bac-
teria (LAB) are of special interest because they are generally
recognized as safe (GRAS). Recombinant LAB expressing
heterologous antigens have been successfully used for vacci-
nation purposes. Immune responses could be elicited against
bacterial and viral antigens [9,10]. Intranasal immunization
led to humoral and cellular responses to HPV-16 E7 [11,10]
and tetanus toxin [12]. Protection was demonstrated in animal
models with a tetanus challenge using recombinant Lacto-
bacillus plantarum [13,14], Streptococcus gordonii [15] and
Lactococcus lactis [16,17] following different immunization
routes (subcutaneous, nasal, oral). Because these recombi-
264-410X/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
oi:10.1016/j.vaccine.2006.03.054
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nant LAB are suitable for mucosal immunization, they seem
particularly useful for the development of vaccines against
pathogens invading the body through the mucosal surface.
This is illustrated by the recent work of Mannam et al. in
which L. lactis cells expressing part of the virulent factor
M provided protection in nasally immunized mice against
a lethal nasal challenge with Streptococcus pyogenes [18].
Although L. lactis and other LAB are safe bacteria, their
widespread use as recombinant strains in mucosal vaccina-
tions may cause unwanted horizontal gene transfer of the
recombinant DNA to other (micro)organisms.
In order to develop a safe and affordable mucosal vac-
cine delivery system we used a system that exploits killed
non-recombinant L. lactis particles obtained by chemical
pretreatment of whole bacteria with hot acid [19,20] (van
Roosmalen et al., in press). These particles are referred to
as Gram-positive enhancer matrix (GEM) and they consti-
tute mainly of bacterial shaped peptidoglycan spheres that
lack other intact cell wall components and intracellular mate-
rial. Here, we studied their use as an antigen carrier and
adjuvant in nasal immunizations. Antigens are attached to
the surface of GEM particles by means of a peptidogly-
can binding domain called the protein anchor (PA). The PA
domain comes from a lactococcal enzyme and it binds with
high affinity to peptidoglycans in a non-covalent manner






























2. Materials and methods
2.1. Bacterial strains and growth conditions
L. lactis NZ9000 used for production of the GEM particles
was grown in M17 broth (Oxoid, Haarlem, The Netherlands)
at 30 ◦C or on M17 agar, both supplemented with 0.5% glu-
cose (GM17). L. lactis PA1001 was used for the production
of recombinant antigens and grown in GLS broth (Strik Spe-
cial Additives, Eemnes, The Netherlands). S. pneumoniae
D39 (NTTC 7466; Central public health laboratory, London,
UK) and TIGR4 [28] were used for ELISA on whole bacteria
and grown in Todd–Hewitt broth (Oxoid) supplemented with
0.5% yeast extract at 37 ◦C.
2.2. Vaccine preparation
The plasmids pPA32, pPA162 and pPA152 were used to
express and secrete the recombinant fusion proteins PpmA-
PA, SlrA-PA and IgA1 protease-PA (IgA1p-PA), respec-
tively. Construction of the plasmids is described elsewhere
(Audouy, manuscript in preparation). Lactococcal GEM par-
ticles were produced as described before [20,21]. Culture
supernatants containing the fusion recombinant proteins were
concentrated with a VivaFlow (Vivascience VivaFlow200,
























rA genetic constructs were prepared with three antigens
f Streptococcus pneumoniae (S. pneumoniae): the putative
roteinase maturation protein A (PpmA); the streptococcal
ipoprotein rotamase A (SlrA); and the immunoglobulin A1
rotease (IgA1p). S. pneumoniae can cause severe disorders
s pneumonia, meningitis and septicaemia upon infection.
he classical vaccine approach for this pathogen makes use
f capsule polysaccharide-antigens. However, several candi-
ates protein-antigens were isolated and promising results
ere obtained in animals models of infection by S. pneumo-
iae [20–24]. SlrA and IgA1p were recently demonstrated
o be immunogenic in humans [25]. PpmA is able to induce
ntibodies with opsonophagocytic activity [26]. PpmA anti-
odies in humans are associated with a decreased risk of
titis Media [27]. All three antigens are immunogenic, sur-
ace located and can induce antibodies in young children
25].
After expression in a suitable host to obtain secreted
ntigen-PA fusion proteins and binding to the GEM parti-
les, the obtained vaccines were characterized in vivo studies.
o demonstrate the adjuvanticity of GEM particles, serum
ntibody responses were measured after nasal immunization
ith different vaccine formulations of SlrA, with or without
EM particles. We also investigated the effect of a preex-
sting anti-carrier immune response on the development of
ntigen-specific antibodies when two different vaccines were
sed consecutively in the same mice. We then prepared GEM-
ased vaccines with SlrA, PpmA and IgA1p and studied the
ocal and systemic responses obtained after intranasal immu-
ization.ixing the concentrates with GEM particles under gentle
gitation for 30 min at room temperature. The amount of
ound antigen-PA was estimated using coomassie brilliant
lue (CBB) stained gels and comparison to bovine serum
lbumin (BSA) protein standards. Monovalent vaccines con-
isted of 2.5 × 109 GEMs and contained 6g IgA1p-PA,
7g PpmA-PA or 73g SlrA-PA, per dose. The trivalent
accine was prepared by mixing the three monovalent vac-
ines in a ratio 1:1:1 and thus, contained a third of the amount
f antigen present in the monovalent vaccines for each anti-
en.
.3. Production and puriﬁcation of his-tag fusions
SlrA-His (pET11-SlrA), PpmA-His (pET11-PpmA) and
gA1p-His (pET11-IgA1 protease) with a C-terminal his-tag
25] were produced in E. coli BL21(DE3) using IPTG induc-
ion and purified by his-tag isolation for coating of ELISA
lates.
.4. Immunization and sample collection
Outbred female CD-1 mice (6 weeks old) were purchased
rom Harlan (Gannat, France). Mice were maintained under
pecified pathogen-free (SPF) conditions and received water
nd food ad libitum. All animal experiments were performed
ith approval of the Animal Experimentation Committee of
he University of Groningen (Groningen, The Netherlands).
ntranasal immunization was performed under light isoflu-
ane inhalation anaesthesia. Mice were held on their backs
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and 20l of vaccine or control was gently applied onto the
nostrils using a standard research pipet. Complete immu-
nization consisted of three doses given at 10-day intervals,
each containing 2.5 × 109 GEM particles. At termination,
blood samples were collected by cardiac puncture and supple-
mented with heparin. After centrifugation, plasma was stored
at −20 ◦C until use. A small incision was made in the trachea
for insertion of a small tube connected to a syringe to col-
lect nasal and lung lavages. Lung washes were performed
by injection of PBS into the lung followed by aspiration of
the lavage fluid. Nasal washes were performed by aspiration
of PBS and ejection of the lavage fluid through the nostrils.
Nose and lung washes were collected, respectively, in 0.5 ml
and 1 ml PBS containing protease inhibitor (Complete Pro-
tease Inhibitor Cocktail, Roche, Almere, The Netherlands).
Samples were kept at 4 ◦C until testing on the following day.
2.5. Detection of speciﬁc antibodies by ELISA
To determine the concentrations of specific anti-PpmA,
-IgA1p, and -SlrA IgGs and IgAs an ELISA procedure
was used. Briefly, high-binding capacity microtiterplates
(Greiner, Haarlem, The Netherlands) were coated with SlrA-
His (0.2g/well), PpmA-His (0.2g/well) or IgA1p-His
(1g/well) in 0.05 M carbonate buffer (pH 9.6) overnight




























incubated with anti-mouse IgG alkaline phosphatase conju-
gate (Sigma) as second antibody and stained with NBT and
BCIP using standard procedures.
3. Results
3.1. Formulation of the vaccine
The ability of the GEM particles to act as carrier and
adjuvant was tested with the pneumococcal antigen SlrA.
Only background levels of SlrA-specific IgGs were mea-
sured when purified SlrA was administered in the absence
of any adjuvant (Fig. 1) and two mice in this group (n = 6)
remained sero-negative. When SlrA was bound to or mixed
with the GEM particles, high levels of serum IgGs were
produced (significantly higher compared to levels obtained
with purified SlrA (P-values <0.005)). The highest levels
were obtained when SlrA was attached to the GEM particles.
There was no significant difference (P = 0.44) between the
bound and mixed groups and all mice in these groups (n = 6)
showed sero-conversion. Interestingly, when the GEM parti-
cles were administered 24 h prior to antigen administration,
still an increase in IgG production was found compared to
immunization with the antigen alone (P < 0.05). However,














(ween 20, then incubated 1 h with 1% BSA in PBS/Tween.
era were diluted appropriately and added to the plates in
hree-fold dilutions and incubated for 2 h at room temper-
ture. After washing, the alkaline phosphatase secondary
ntibody directed to mouse IgG-Fc or mouse IgA (Sigma,
wijndrecht, The Netherlands) was incubated for 1.5 h at a
ilution of 1:5000. Colorimetric reaction was obtained by
ddition ofp-nitrophenyl phosphate substrate (Sigma) diluted
n 0.05 M carbonate buffer (pH 9.6) supplemented with 1M
gCl2. The enzymatic reaction was stopped with NaOH and
bsorption was measured at 405 nm. Concentrations were cal-
ulated from a calibration curve made with purified mouse
gG (Sigma). IgG antibodies against whole S. pneumoniae
acteria were evidenced following the same ELISA proto-
ol. The plates were coated with heat-inactivated bacteria
107/well) in carbonate buffer overnight at 4 ◦C.
.6. Immunoblotting
The level of serum antibodies against GEM components
as determined by Western blotting. GEM particles were
sed untreated or treated with lysozyme to break down the
ell wall. For lysozyme treatment, GEM particles were incu-
ated for 1 h at 55 ◦C in lysis buffer (50 mM Tris–HCl, pH
.0; 10 mM EDTA; 0.1 mg lysozyme). A protein gel was run
ith the samples, containing the equivalent of 5 × 108 GEM
articles per lane, and Western blots were incubated with
100× dilution of pooled sera from mice which received
o vaccine (pre-immune), three doses of GEM vaccine (3×
EM) or six doses of GEM vaccine (6× GEM). The blot wasion obtained when the antigen and the particles were given
t the same time. The ability of the GEM particles to increase
he systemic antibody response against SlrA clearly demon-
trates their natural adjuvant properties.
.2. Effect of preexisting anti-carrier antibodies
We evaluated the effect of a preexisting antibody response
gainst the GEM particles and protein anchor on a subse-
uent immunization with a GEM-based vaccine. Four groups
ig. 1. Concentrations of anti-SlrA IgG antibodies in serum after three nasal
mmunizations with SlrA in different formulations: GEM particles with
ound protein anchor-SlrA fusion product (GEM-SlrA bound), GEM parti-
les mixed with purified SlrA (GEM-SlrA mixed), GEM particles adminis-
ered 24 h prior administration of purified SlrA (SlrA GEM priming) or puri-
ed SlrA alone. Bars represent average concentrations per group + S.E.M.
n = 6).
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Table 1
Immunization schedule for consecutive immunizations and specific IgG concentrations (g/ml) after the first immunization series
Group First immunization series Specific IgG (g/ml) Second immunization series
PA SlrA PpmA
1 PBS 0 0 0 GEM-PpmA
2 GEM-SlrA 68 ± 19 223±50 0 GEM-PpmA
3 PBS 0 0 0 GEM-SlrA
4 GEM-PpmA 78 ± 39 0 207 ± 103 GEM-SlrA
Results are averages/group ± S.E.M. (n = 6).
of mice (n = 6) received first a series of three nasal immu-
nizations according to the schedule in Table 1. A second
immunization series was started three months later. One week
after the first immunization series and one day before the
second series, serum samples of all mice were analyzed
for the presence of SlrA, PpmA and PA specific IgGs. At
both time points high concentrations of circulating IgG anti-
bodies against the pneumococcal antigens and PA could be
detected in the two groups that received GEM-based vac-
cines (Table 1). We found no decrease in these antibody
levels during the three month intervals between both immu-
nization series (data not shown). No specific antibodies were
found in the mice treated with PBS. Mice first immunized
with GEM-SlrA received a second series of nasal immuniza-
tions with GEM-PpmA. Similarly, mice first immunized with
GEM-PpmA received a second series of nasal immuniza-
tions with GEM-SlrA. Mice pretreated with PBS received
either a GEM-PpmA or a GEM-SlrA vaccine (Table 1).
Similar anti-PpmA (Fig. 2A) and anti-SlrA (Fig. 2B) IgG
levels were raised regardless of the pretreatment that the
mice received during the first immunization, i.e. a different
GEM-based vaccine or PBS. In addition, the development
of specific IgGs followed the same kinetics in PBS and vac-
cine pretreated mice. Already after a single administration
measurable amounts of anti-PpmA and anti-SlrA IgGs were




















Anti-PA antibodies were raised upon immunization with
the GEM-PpmA and GEM-SlrA vaccines as shown in Table 1
and specific IgG levels were comparable in both cases. How-
ever, anti-PA IgG levels were about a factor 3 lower compared
to the levels of IgGs induced against the pneumococcal anti-
gens.
To evaluate the immune response against the components
of the empty GEM carrier particle, Western blots contain-
ing GEM and lysozyme-treated GEM were incubated with
the sera of mice which received three doses of GEM vac-
cine (3× GEM) or six doses of GEM vaccine (6× GEM).
Fig. 2. Consecutive nasal immunizations with GEM-based vaccines car-
rying different antigens. Specific anti-PpmA (A) and anti-SlrA (B) IgG
concentrations in serum after the first, second and third dose of the sec-
ond immunization series of the GEM-PpmA (A) or GEM-SlrA (B) vaccine.
The first series of immunizations contained either PBS or a GEM-based vac-
cine, as indicated on the x-axis. Bars represent average concentrations per
group + S.E.M. (n = 6); (*) not determined.nd and third administration which is characteristic of an
daptive response and indicates that immunological memory
as developed. When a first immunization series with GEM-
pmA was started in mice at the age of 6 weeks or 22 weeks
group 1 and 4 in Table 1), the concentrations of specific
gG antibodies 10 days after the third dose were 207g/ml
nd 229g/ml, respectively. A similar observation was made
or the GEM-SlrA vaccine, with average concentrations of
23g/ml in the young and 163g/ml in the older mice.
erum IgA levels for PpmA and SlrA were also measured
fter all immunizations. Systemic anti-PpmA IgA concentra-
ions were 0.61 (±0.27)g/ml and 1.9 (±0.63)g/ml when
he GEM-PpmA vaccine was given in naı¨ve or preimmu-
ized mice, respectively. Systemic anti-SlrA IgA concentra-
ions were 11.9 (±5.9)g/ml and 5.3 (±1.7)g/ml when
he GEM-SlrA vaccine was given in naı¨ve or preimmunized
ice, respectively. The differences were not statistically sig-
ificant (P = 0.09 and 0.3 in the case of PpmA and SlrA,
espectively).
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Fig. 3. Antibody response against the GEM carrier detected by immunoblot-
ting. The GEM proteins on the blot were either released from intact GEM
particles or from lysozyme treated GEM particles (lysate). The blots were
incubated with a 100 times dilution of pooled sera from mice that received no
vaccine (pre-immune), three doses of GEM-based vaccine (3× GEM) or six
doses of GEM-based vaccine (6× GEM). The marker in the first lane con-
tains proteins with sizes from top to bottom of 250 kDa, 150 kDa, 100 kDa,
75 kDa, 50 kDa, 37 kDa, 25 kDa and 20 kDa.
Preimmune serum was used as a control (see Fig. 3). After
three immunizations with GEM-based vaccines, the antibody
response against the carrier is very low. After six immuniza-
tions, however, antibodies were detected against the proteins
that are still present in low amounts in the GEM particles.
These remaining proteins were best visualized in the lane with
the lysozyme-treated GEM sample, suggesting that these are
intracellular proteins. This was corroborated by the fact that
no antibody binding to intact GEM particles could be demon-
strated in immunofluorescence assays when GEM particles
had been incubated with serum of mice that received six doses
of GEM-based vaccine (results not shown).
Taken together, these results clearly indicate that pre-
existing immune responses against the carrier and a given
antigen-PA fusion are not detrimental for the induction of
systemic and mucosal immune responses against a different
antigen-PA fusion using the same delivery system and the
same immunization route. Moreover, the immune response
measured was not dependant of the age of the mice at the
time of priming.
3.3. Local antibody response
We then examined the local antibody response after nasal
immunization against three pneumococcal antigens. SlrA-,




Fig. 4. Specific anti-PpmA, -IgA1p and -SlrA IgA (A) concentrations in
nasal and lung washes after nasal immunization with GEM-based monova-
lent vaccines. Specific anti-PpmA, -IgA1p, and -SlrA IgG (B) concentrations
in lung washes, after nasal immunization with GEM monovalent vaccines.
Bars represent average concentrations per group + S.E.M. (n = 3–5).
in the nasal and the lung secretions (Fig. 4A). All antigens
induced IgA production at both locations. However, IgA con-
centrations against SlrA and PpmA were significantly higher
than the IgA concentration against IgA1p. In the lung washes,
IgG antibodies were the most abundant immunoglobin class
(Fig. 4B) with much higher concentrations compared to the
antigen-specific IgA antibodies. The anti-IgA1p IgG level
was lower compared to levels of IgG against the two other
antigens, consistent with IgA production patterns in the nose
and lungs. From these results we can conclude that the
mucosal immune system was efficiently triggered upon nasal
immunization with the GEM-based vaccines and reacted with
adapted effector responses.
3.4. Systemic antibody response
The vaccine-induced systemic response was evaluated
by measuring specific IgG levels in serum when the anti-
gens were administered individually (Fig. 5A) or all together
(Fig. 5B). Each antigen induced the production of circulating
specific antibodies when given as a monovalent GEM-antigen
vaccine (Fig. 5A). Concentrations of anti-SlrA (277g/ml
average) and anti-PpmA (207g/ml average) IgGs were
comparable, while anti-IgA1p IgG levels were much lower
(7g/ml average). These concentrations of IgG antibodies
reflect the trend observed at the mucosal level. The three anti-
gally to the GEM particles and mice were immunized with
single monovalent vaccine. Specific IgA antibodies, the
ajor characteristic of mucosal immunity, were measured ens were then administered together in a trivalent vaccine
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Fig. 5. Specific anti-PpmA, -IgA1p and -SlrA IgG concentrations in serum,
after nasal immunization with GEM-based monovalent vaccines (A) or triva-
lent vaccine (B). Bars represent average concentrations per group + S.E.M.
(A, n = 5; B, n = 10).
which consisted for each antigen of a third of the mono-
valent vaccine. Although only a third of each antigen dose
from the monovalent vaccines was present in the trivalent
vaccine, the IgG response developed against each antigen
after nasal immunization was similar to the response obtained
with the monovalent vaccines (Fig. 5B). This observation
implies that the amount of antigens bound to the GEM par-
ticles was above the optimum for the induction of the IgG
response or that the combination of the vaccines had a posi-
tive effect on this response. No negative interactions between
the antigens were observed. Interestingly, the serum from
mice immunized with the trivalent vaccine did not only
recognize the purified antigens but also contained antibod-
ies able to bind intact S. pneumoniae bacteria, strains D39
and TIGR4 (Table 2). Taken together, these data show that
Table 2
ELISA on whole bacteria




Trivalent vaccine 0.12 2.70
Pooled serum (diluted 1/100) from mice nasally immunized with PBS or the




mucosal vaccination with GEM-based vaccines results in a
systemic humoral response. In addition, the GEM system can
be used to immunize against multiple antigens simultane-
ously and more specifically, SlrA, PpmA and IgA1 protease
can be combined in a trivalent vaccine.
4. Discussion
In the work presented here we characterize a vaccine deliv-
ery and adjuvant system based on killed non-recombinant L.
lactis particles (GEM) displaying antigens on their surface by
means of a peptidoglycan binding domain. Our approach dif-
fers in several aspects from the use of recombinant lactic acid
bacteria producing heterologous proteins as antigens. How-
ever, as with live L. lactis cells, the GEM particles possess
strong adjuvant properties [29]. Further comparison of both
strategies is difficult because of the differences in antigens
used, in antigens concentrations and in numbers of bacterial
cells/GEM particles delivered. Several authors working with
live recombinant LAB, showed that stronger responses were
mounted when the antigen was bound to the membrane/cell-
wall compared to secreted or intracellularly located antigen
[10,16,30]. Usually these studies neglected the effect of anti-
gen dose because a standard number of bacteria were given





























htrains D39 and TIGR4 and the GEM-based trivalent vaccine coated on a
icrotiter plate. Optical density values from a standard ELISA test are shown
OD measured at 405 nm).nt amounts of antigen according to the antigen destination
10,30]. In our study the amount of antigen in each for-
ulation was adjusted quite accurately. The difference we
bserved between bound or mixed was less pronounced (sta-
istically not significant) than in the above-mentioned studies.
n explanation might be that we used a relative high dose
f the SlrA antigen. Differences between mixed and bound
ay become significant when lower amounts of antigen are
dministered. Further investigations are required to under-
tand the effect of binding to the GEM through the PA domain
n the development of an immune response. The observation
f enhanced antibody responses to SlrA when the GEM parti-
les were given 24 h prior to the antigen implies that complex
actors play a role. The GEM particles seem to place the ini-
iation site of the immune response into a ‘receptive’ state for
he antigen and this could be the result of inducing the expres-
ion of co-stimulatory molecules on antigen-presenting cells
r the release of cytokines as TNF-. These issues should
e addressed not only with SlrA but also with other antigens
o rule out an antigen-related effect. Regardless of the effect
f attachment of the antigen to the carrier on the immune
esponse, the strong binding of antigen-PA fusion proteins to
he peptidoglycan layer of the GEM particles provide an effi-
ient and rapid purification method for the antigen, thereby
acilitating easy formulation of the vaccine.
Low levels of IgG were developed against intracellular
rotein remnants in the GEM particles, which is consistent
ith the finding of others that L. lactis cells have a low intrin-
ic immunogenicity [16,17]. In addition, these antibodies
ardly recognize intact GEM particles. After six adminis-
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trations of the GEM vaccine antibodies react with GEM pro-
teins in the Western blot. The SDS–PAGE treatment without
lysozyme does lyse some of the GEM particles. Therefore,
the proteins that light up in the Western blots are likely to
be intracellular proteins. This was corroborated by the fact
that reaction of the antiserum with the intact GEM parti-
cles was not detected using immunofluorescent microscopy.
Consequently, the antiserum does not contain antibodies that
recognize surface components of the GEM particles. We
also showed that the preexisting antibody responses to the
GEM-PA complex did not hamper the development of sys-
temic and mucosal antigen-specific antibody responses upon
nasal vaccination. Several studies have addressed the ques-
tion of preexisting immunity against the CT/CTB adjuvant
in combination with antigens of different nature, e.g. dex-
tran [31], influenza virus [32], and capsular polysaccharide
[33]. In the latter case, divergent findings were made, as
either increase or inhibition of the anti-CPS response was
seen after priming with the toxin [33,34]. Wu and Russell
showed with a bacterial protein antigen that the development
of salivary IgA and serum IgG responses were largely unaf-
fected by a pre-immunization against CT when a CT-antigen
conjugate was used for subsequent immunization [35]. Simi-
larly, our data showed that antigen-specific systemic antibody
levels developed to a similar level with or without preexist-






























pared to SlrA and PpmA. An obvious explanation is that the
mice received a considerable lower amount of IgA1p per dose
than that for SlrA or PpmA. However, further investigation is
needed to reveal whether the dose or the immunogenicity of
IgA1p is the crucial factor on this point. The IgA1p present in
the GEM vaccines is a truncated antigen, lacking enzymatic
activity, which excludes cleavage of nose IgAs by the antigen.
In summary, the work presented in this paper addressed
critical aspects of nasal immunization with GEM-based
vaccines. We showed that the IgG antibody response induced
against a pneumococcal antigen was dramatically increased
by the GEM particles compared to antigen alone. Two
subsequent immunization series with different GEM-based
vaccines could be performed without affecting the systemic
antibody response to a specific antigen, compared to single
immunization against the same antigen. Furthermore, we
demonstrated that GEM-based vaccines elicited mucosal and
systemic antibody responses against three pneumococcal
antigens following nasal immunization, without additional
adjuvants. Taken together, these results clearly illustrate
the potential of the GEM-system for the development of
mucosal vaccines against S. pneumoniae in particular and




Rucosal IgA anti-polysaccharide were reduced when a anti-
T response was previously induced intranasally [31,33].
owever, this effect was reversed when the immunization
as done three months after the anti-CTB priming, while anti-
TB titers were still high [31]. Bergquist at al. [31] suggested
hat local memory T-cell specific for the carrier/adjuvant
ould help the initiation of the mucosal response. Indeed
hese authors saw a slight increase in IgA anti-dextran levels
n the lungs when mice were vaccinated with dextran-CTB
onjugate three months after CTB priming. Measurement
f the local immunoglobulins in our experimental set-up
ay provide useful information to understand mechanisms
f inhibition/enhancement. In contrast to the referred studies
here the pre-immunization was performed with the adjuvant
nly, we used two complete vaccines successively, which bet-
er reflects a practical situation. In addition, administration
chedules appear to be a critical parameter and although we
sed a different vaccine delivery system, the same may hold
rue in our case. These complex and, in our view, critical
ssues deserve more investigations.
Lactic acid bacteria seem promising organisms for vac-
ination against S. pneumoniae. We showed in the present
ork expression of three pneumococcal antigens in L. lactis.
xpression of pneumococcal surface antigen A (PsaA) and
neumococcal surface protein A (PspA) was already reported
n L. casei [36] and L. lactis (Leenhouts, manuscript in prepa-
ation). Furthermore, IgA and IgG antibodies were developed
gainst these antigens when fused to PA and displayed on
he lactococcal GEM particles for nasal immunization. The
gA1p antigen induced much lower antibody responses com-The authors thank Louwe de Vries for excellent technical
ssistance. The authors also thank Marijke Haas and Bart Jan
roesen for stimulating discussions.
eferences
[1] Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005;23:
1804–13.
[2] Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat
Med 2005;11:S45–53.
[3] Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Comparative
immunomodulatory properties of a chitosan-MDP adjuvant combi-
nation following intranasal or intramuscular immunisation. Vaccine
2005;23:1923–30.
[4] Libon C, Haeuw JF, Crouzet F, Mugnier C, Bonnefoy JY, Corvaia N.
Streptococcus pneumoniae polysaccharides conjugated to the outer
membrane protein A from Klebsiella pneumoniae elicit protective
antibodies. Vaccine 2002;20:2174–80.
[5] Chabot S, Brewer A, Lowell G, Plante M, Cyr S, Burt DS, et al.
A novel intranasal ProtollinTM-based vaccine induces mucosal and
systemic neutralizing antibody responses and cell-mediated immunity
in mice. Vaccine 2005;23:1374–83.
[6] Bizanov G, Janakova L, Knapstad SE, Karlstad T, Bakke H, Haugen
IL, et al. Immunoglobulin-A antibodies in upper airway secretions
may inhibit intranasal influenza virus replication in mice but not
protect against clinical illness. Scand J Immunol 2005;61:503–10.
[7] Berstad AKH, ANdersen SR, Dalseg R, Drømtorp S, Holst J,
Namork E, et al. Inactivated meningococci and pertussis bacteria
are immunogenic and act as mucosal adjuvants for a nasal inacti-
vated influenza virus vaccine. Vaccine 2000;18:1910–9.
[8] Haugan A, Thi Dao PX, Glende N, Bakke H, Haugen IL, Janakova
L, et al. Bordetella pertussis can act as adjuvant as well as inhibitor
of immune responses to non-replicating nasal vaccines. Vaccine
2003;22:7–14.
S.A.L. Audouy et al. / Vaccine 24 (2006) 5434–5441 5441
[9] Xin K-Q, Hoshino Y, Toda Y, Igimi S, Kojima Y, Jounai N, et
al. Immunogenicity and protective efficacy of orally administered
recombinant Lactococcus lactis expressing surface-bound HIV env.
Blood 2003;102:223–8.
[10] Bermu´dez-Humara´n LG, Cortes-Perez NG, Le Loir Y, Alcocer-
Gonza´lez JM, Tamez-Gurra RS, Montes de Oca-Luna R, et al. An
inducible surface presentation system improves cellular immunity
against human papillomavirus type 16 E7 antigen in mice after
nasal administration with recombinant lactococci. J Med Microbiol
2004;53:427–33.
[11] Cortes-Perez NG, Bermu´dez-Humara´n LG, Le Loir Y, Rodriguez-
Padilla C, Gruss A, Saucedo-Cardenas O, et al. Mice immunization
with live lactococci displaying a surface anchored HPV-16 E7 onco-
protein. FEMS Microbiol Lett 2003;229:37–42.
[12] Robinson K, Chamberlain LM, Lopez MC, Rush CM, Marcotte H,
Le Page RWF, et al. Mucosal and cellular immune responses elicited
by recombinant Lactococcus lactis strains expressing tetanus toxin
fragment C. Infect Immun 2004;72:2753–61.
[13] Grangette C, Mu¨ller-Alouf H, Goudercourt D, Geoffroy M-C,
Turneer M, Mercenier A. Mucosal immune responses and protection
against tetanus toxin after intranasal immunization with recombinant
Lactobacillus plantarum. Infect Immun 2001;69:1547–53.
[14] Grangette C, Muller-Alouf H, Geoffroy M, Goudercourt D, Turneer
M, Mercenier A. Protection against tetanus toxin after intra-
gastric administration of two recombinant lactic acid bacteria:
impact of strain stability and in vivo persistence. Vaccine 2002;20:
3304–9.
[15] Medaglini D, Ciabattini A, Spinosa MR, Maggi T, Marcotte H,
Oggioni MR, et al. Immunization with recombinant Streptococcus
gordonii expressing tetanus toxin fragment C confers protection from








[23] Hamel J, Charland N, Pineau I, Ouellet C, Rioux S, Martin D, et al.
Prevention of pneumococcal disease in mice immunized with con-
served surface-accessible proteins. Infect Immun 2004;72:2659–70.
[24] Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, Paton JC.
Immunization of mice with combinations of pneumococcal virulence
proteins elicits enhanced protection against challenge with Strepto-
coccus pneumoniae. Infect Immun 2000;68:3028–33.
[25] Adrian PV, Bogaert D, Oprins M, Rapola S, Lahdenkari M,
Kilpi T, et al. Development of antibodies against pneumococcal
proteins alpha-enolase, immunoglobulin A1 protease, streptococcal
lipoprotein rotamase A, and putative proteinase maturation proteinA
in relation to pneumococcal carriage and Otitis Media. Vaccine
2004;22:2737–42.
[26] Overweg K, Kerr A, Sluijter M, Jackson MH, Mitchell TJ, de Jong
AP, et al. The putative proteinase maturation protein A of Strepto-
coccus pneumoniae is a conserved surface protein with potential to
elicit protective immune responses. Infect Immun 2000;68:4180–8.
[27] Bogaert D, Holmlund E, Lahdenkari M, de Groot R, Kilpi T, Her-
mans PW, et al. Development of antibodies against the putative
proteinase maturation protein A in relation to pneumococcal carriage
and otitis media. FEMS Immunol Med Microbiol 2006;46:166–8.
[28] Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, et
al. Complete genome sequence of a virulent isolate of Streptococcus
pneumoniae. Science 2001;293:498–506.
[29] Norton PM, Wells JM, Brown HWG, Macpherson AM, Le Page
RWF. Protection against tetanus toxin in mice nasally immunized
with recombinant Lactococcus lactis expressing tetanus toxin frag-
ment C. Vaccine 1997;15:616–9.
[30] Reveneau N, Geoffroy MC, Locht C, Chagnaud P, Mercenier A.
Comparison of the immune responses induced by local immu-






[16] Norton PM, Brown HWG, Wells JM, Macpherson AM, Wilson PW,
Le Page RWF. Factors affecting the immunogenicity of tetanus toxin
fragment C expressed in Lactococcus lactis. FEMS Immunol Med
Microbiol 1996;14:167–77.
17] Robinson K, Chamberlain LM, Schofiled KM, Wells JM, Le Page
RWF. Oral vaccination of mice against tetanus with recombinant
Lactococcus lactis. Nat Biotechnol 1997;15:653–7.
18] Mannam P, Jones KF, Geller BL. Mucosal vaccine made from
live, recombinant Lactococcus lactis protects mice against pha-
ryngeal infection with Streptococcus pyogenes. Infect Immun
2004;72:3444–50.
19] Steen A, Buist G, Leenhouts KJ, El Khatabbi M, Grijpstra F, Zomer
AL, et al. Cell wall attachment of a widely distributed pepdidoglycan
binding domain is hindered by cell wall constituents. J Biol Chem
2003;278:23874–81.
20] van Roosmalen ML, Kanninga R, El Khatabbi M, Neef J, Audouy
S, Bosma T, et al. Mucosal vaccine delivery of antigens tightly
bound to an adjuvant particle made from food-grade bacteria. Meth-
ods 2006;38:144–9.
21] Bosma T, Kanninga R, Neef J, Audouy SAL, van Roosmalen ML,
Steen A, et al. Novel surface display system for proteins on non-
genetically modified Gram-positive bacteria. Appl Environ Microbiol
2006;72:880–9.
22] Brown JS, Ogunniyi AD, Woodrow MC, Holden DW, Paton JC.
Immunization with components of two iron uptake ABC transporters
protects mice against systemic Streptococcus pneumoniae infection.
Infect Immun 2001;69:6702–6.tetanus toxin fragment C in different cellular locations. Vaccine
2002;20:1769–77.
31] Bergquist C, Lagergard T, Holgren J. Anticarrier immunity sup-
presses the antibody response to polysaccharide antigens after
intranasal immunization with the polysaccharide-protein conjugate.
Infect Immun 1997;65:1579–83.
32] Tamura S, Funato H, Nagamine T, Aizawa C, Kurata T. Effectiveness
of cholera toxin B subunit as an adjuvant for nasal influenza vacci-
nation despite pre-existing immunity to CTB. Vaccine 1989;7:503–5.
33] Shen X, Lagergard T, Yang Y, Lindblad M, Fredriksson M, Waller-
strom G, et al. Effect of pre-existing immunity for systemic and
mucosal immune responses to intranasal immunization with group
B Streptococcus type III capsular polysaccharide-cholera toxin B
subunit conjugate. Vaccine 2001;19:3360–8.
34] Peeters CC, Tenbergen-Meekes AM, Poolman JT, Beurret M,
Zegers BJ, Rijkers GT. Effect of carrier priming on immuno-
genicity of saccharide-protein conjugate vaccines. Infect Immun
1991;59:3504–10.
35] Wu HY, Russell MW. Comparison of systemic and mucosal priming
for mucosal immune responses to a bacterial protein antigen given
with or coupled to cholera toxin (CT) B subunit, and effects of
pre-existing anti-CT immunity. Vaccine 1994;12:215–22.
36] Oliveira ML, Monedero V, Miyaji EN, Leite LC, Lee Ho P, Perez-
Martinez G. Expression of Streptococcus pneumoniae antigens.
PsaA (pneumococcal surface antigen A) and PspA (pneumococcal
surface protein A) by Lactobacillus casei. FEMS Microbiol Lett
2003;227:25–31.
